<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cell Infect Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Cell Infect Microbiol</journal-id><journal-id journal-id-type="publisher-id">Front. Cell. Infect. Microbiol.</journal-id><journal-title-group><journal-title>Frontiers in Cellular and Infection Microbiology</journal-title></journal-title-group><issn pub-type="epub">2235-2988</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">8131868</article-id><article-id pub-id-type="doi">10.3389/fcimb.2021.672472</article-id><article-categories><subj-group subj-group-type="heading"><subject>Cellular and Infection Microbiology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>P2x7 Receptor Signaling Blockade Reduces Lung Inflammation and Necrosis During Severe Experimental Tuberculosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Santiago-Carvalho</surname><given-names>Igor</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="fn002">
<sup>&#x02020;</sup>
</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/1278955"/></contrib><contrib contrib-type="author"><name><surname>de Almeida-Santos</surname><given-names>Gislane</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="fn002">
<sup>&#x02020;</sup>
</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/1245947"/></contrib><contrib contrib-type="author"><name><surname>Bomfim</surname><given-names>Caio C&#x000e9;sar Barbosa</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref><xref ref-type="author-notes" rid="fn002">
<sup>&#x02020;</sup>
</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/381042"/></contrib><contrib contrib-type="author"><name><surname>de Souza</surname><given-names>Paula Carolina</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/1249231"/></contrib><contrib contrib-type="author"><name><surname>Silva</surname><given-names>Juan Carlo Santos e</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/780289"/></contrib><contrib contrib-type="author"><name><surname>de Melo</surname><given-names>Bruno Marcel Silva</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/1319945"/></contrib><contrib contrib-type="author"><name><surname>Amaral</surname><given-names>Eduardo Pinheiro</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/409055"/></contrib><contrib contrib-type="author"><name><surname>Cione</surname><given-names>Marcos Vin&#x000ed;cios Pinheiro</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/1247486"/></contrib><contrib contrib-type="author"><name><surname>Lasunskaia</surname><given-names>Elena</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/1165448"/></contrib><contrib contrib-type="author"><name><surname>Hirata</surname><given-names>Mario Hiroyuki</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/175190"/></contrib><contrib contrib-type="author"><name><surname>Alves-Filho</surname><given-names>Jos&#x000e9; Carlos Farias</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/32348"/></contrib><contrib contrib-type="author"><name><surname>Nakaya</surname><given-names>Helder Imoto</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/24735"/></contrib><contrib contrib-type="author"><name><surname>Alvarez</surname><given-names>Jos&#x000e9; Maria</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/275499"/></contrib><contrib contrib-type="author"><name><surname>D&#x02019;Imp&#x000e9;rio Lima</surname><given-names>Maria Regina</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref><uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/236258"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Departamento de Imunologia, Instituto de Ci&#x000ea;ncias Biom&#x000e9;dicas (ICB), Universidade de S&#x000e3;o Paulo (USP)</institution>, <addr-line>S&#x000e3;o Paulo</addr-line>, <country>Brazil</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Departamento de An&#x000e1;lises Cl&#x000ed;nicas e Toxicol&#x000f3;gicas, Faculdade de Ci&#x000ea;ncias Farmac&#x000ea;uticas (FCF), USP</institution>, <addr-line>S&#x000e3;o Paulo</addr-line>, <country>Brazil</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Departamento de Farmacologia, Faculdade de Medicina de Ribeir&#x000e3;o Preto, USP</institution>, <addr-line>S&#x000e3;o Paulo</addr-line>, <country>Brazil</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</institution>, <addr-line>Bethesda, MD</addr-line>, <country>United States</country>
</aff><aff id="aff5">
<sup>5</sup>
<institution>Laborat&#x000f3;rio de Biologia do Reconhecer, Universidade Estadual do Norte Fluminense Darcy Ribeiro</institution>, <addr-line>Campos dos Goytacazes</addr-line>, <country>Brazil</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Selvakumar Subbian, Public Health Research Institute (PHRI), United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Noria Segueni, Artimmune SAS, France; Monica Varela, Leiden University, Netherlands</p></fn><corresp id="fn001">*Correspondence: Caio C&#x000e9;sar Barbosa Bomfim, <email xlink:href="mailto:caiocesarbonfim@usp.br" xlink:type="simple">caiocesarbonfim@usp.br</email>; Maria Regina D&#x02019;Imp&#x000e9;rio Lima, <email xlink:href="mailto:relima@usp.br" xlink:type="simple">relima@usp.br</email>
</corresp><fn fn-type="equal" id="fn002"><p>&#x02020;These authors have contributed equally to this work and share first authorship</p></fn><fn fn-type="other" id="fn003"><p>This article was submitted to Clinical Microbiology, a section of the journal Frontiers in Cellular and Infection Microbiology</p></fn></author-notes><pub-date pub-type="epub"><day>05</day><month>5</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>11</volume><elocation-id>672472</elocation-id><history><date date-type="received"><day>25</day><month>2</month><year>2021</year></date><date date-type="accepted"><day>20</day><month>4</month><year>2021</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2021 Santiago-Carvalho, Almeida-Santos, Bomfim, Souza, Silva, Melo, Amaral, Cione, Lasunskaia, Hirata, Alves-Filho, Nakaya, Alvarez and D&#x02019;Imp&#x000e9;rio Lima</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Santiago-Carvalho, Almeida-Santos, Bomfim, Souza, Silva, Melo, Amaral, Cione, Lasunskaia, Hirata, Alves-Filho, Nakaya, Alvarez and D&#x02019;Imp&#x000e9;rio Lima</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>The risk of developing severe forms of tuberculosis has increased by the acquired immunodeficiency syndrome (AIDS) epidemic, lack of effective drugs to eliminate latent infection and the emergence of drug-resistant mycobacterial strains. Excessive inflammatory response and tissue damage associated with severe tuberculosis contribute to poor outcome of the disease. Our previous studies using mice deficient in the ATP-gated ionotropic P2X7 receptor suggested this molecule as a promising target for host-directed therapy in severe pulmonary tuberculosis. In this study, we assessed the effects of P2X7 pharmacological blockade on disease severity. First, we observed an increase in <italic>P2RX7</italic> gene expression in the peripheral blood of tuberculosis patients compared to healthy donors. Lung leukocytes of mice infected with hypervirulent mycobacteria also showed increased expression of the P2X7 receptor. P2X7 blockade in mice with advanced tuberculosis recapitulated in many aspects the disease in P2X7-deficient mice. P2X7-directed therapy reduced body weight loss and the development of inflammatory and necrotic lung lesions, as well as delayed mycobacterial growth. Lower TNF-&#x003b1; production by lung cells and a substantial reduction in the lung GR-1<sup>+</sup> myeloid cell population were observed after P2X7 inhibition. The effector CD4<sup>+</sup> T cell population also decreased, but IFN-&#x003b3; production by lung cells increased. The presence of a large population with characteristics of myeloid dendritic cells, as well as the increase in IL-6 production by lung cells, also indicate a qualitative improvement in the pulmonary immune response due to P2X7 inhibition. These findings support the use of drugs that target the P2X7 receptor as a therapeutic strategy to improve the outcome of pulmonary tuberculosis.</p></abstract><kwd-group><kwd> tuberculosis</kwd><kwd> lung damage</kwd><kwd>adjuvant treatment</kwd><kwd> P2X7 receptor</kwd><kwd>host-direct therapies</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa do Estado de S&#x000e3;o Paulo<named-content content-type="fundref-id">10.13039/501100001807</named-content></funding-source></award-group><award-group><funding-source id="cn002">Conselho Nacional de Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico<named-content content-type="fundref-id">10.13039/501100003593</named-content></funding-source></award-group><award-group><funding-source id="cn003">Conselho Nacional de Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico<named-content content-type="fundref-id">10.13039/501100003593</named-content></funding-source></award-group><award-group><funding-source id="cn004">Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa do Estado de S&#x000e3;o Paulo<named-content content-type="fundref-id">10.13039/501100001807</named-content></funding-source></award-group><award-group><funding-source id="cn005">Conselho Nacional de Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico<named-content content-type="fundref-id">10.13039/501100003593</named-content></funding-source></award-group><award-group><funding-source id="cn006">Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa do Estado de S&#x000e3;o Paulo<named-content content-type="fundref-id">10.13039/501100001807</named-content></funding-source></award-group><award-group><funding-source id="cn007">Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa do Estado de S&#x000e3;o Paulo<named-content content-type="fundref-id">10.13039/501100001807</named-content></funding-source></award-group><award-group><funding-source id="cn008">Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa do Estado de S&#x000e3;o Paulo<named-content content-type="fundref-id">10.13039/501100001807</named-content></funding-source></award-group></funding-group><counts><fig-count count="5"/><table-count count="0"/><equation-count count="0"/><ref-count count="50"/><page-count count="11"/><word-count count="5137"/></counts></article-meta></front><body><sec id="s1"><title>Highlights</title><p>The P2X7 receptor detects ATP released during stress or cell death and activates the NLRP3 inflammasome, leading to mature IL-1&#x003b2; and IL-18 secretion and cell death by pyroptosis. Notably, prolonged stimuli of the P2X7 receptor induce necrotic cell death due to formation of large pores in the cell membrane. The P2X7 receptor has been previously suggested as a promising target candidate for host-directed therapies in severe pulmonary tuberculosis. In this study, we provide proof of concept for this approach in mice infected with hypervirulent mycobacteria. P2X7-directed therapy administered over a short period of time in mice with advanced pulmonary tuberculosis was effective in reducing disease severity. This therapeutic strategy can be particularly useful, combined with anti-microbial drugs, to interrupt the vicious cycle of uncontrolled inflammatory response and damage to lung tissue in severe forms of the disease.</p></sec><sec sec-type="intro" id="s2"><title>Introduction</title><p>Tuberculosis (TB) is an airborne infectious disease that remains as one of the major causes of health threat (<xref rid="B49" ref-type="bibr">World Health Organization, 2020</xref>). In 2019, the estimated number of fatal cases resulting from <italic>Mycobacterium tuberculosis</italic> infection reached 1.4 million worldwide, making TB one of the top ten causes of global death (<xref rid="B49" ref-type="bibr">World Health Organization, 2020</xref>). Multiple immune evasion strategies developed along the coevolution of mycobacteria with the vertebrate host, such as the interference with antigen presentation by major histocompatibility complex (MHC) class II molecules, explain the limited success of vaccines against TB (<xref rid="B17" ref-type="bibr">Ernst, 2018</xref>). TB control is also hampered by the acquired immunodeficiency syndrome (AIDS) epidemic, lack of effective drugs to eliminate latent infection as well as the emergence of drug-resistant mycobacterial strains (<xref rid="B42" ref-type="bibr">Shah et&#x000a0;al., 2007</xref>; <xref rid="B49" ref-type="bibr">World Health Organization, 2020</xref>). Failure to prevent and control <italic>M. tuberculosis</italic> infection increases the risk of developing severe forms of TB (<xref rid="B10" ref-type="bibr">Caws et&#x000a0;al., 2008</xref>; <xref rid="B5" ref-type="bibr">Bell and Noursadeghi, 2018</xref>). Severe disease is commonly associated with exacerbated lung inflammation and necrosis, resulting in serious sequelae for TB patients.</p><p>This emerging scenario has encouraged the combined use of standard anti-microbial treatments for TB with host-directed therapies based on anti-inflammatory interventions. This therapeutic approach directly targets the inflammatory response triggered by the infection to prevent and repair tissue damage, promote pathogen elimination and reduce disease sequelae (<xref rid="B27" ref-type="bibr">Kaufmann et&#x000a0;al., 2014</xref>; <xref rid="B50" ref-type="bibr">Zumla et&#x000a0;al., 2016</xref>; <xref rid="B46" ref-type="bibr">Tsenova and Singhal, 2020</xref>). Accelerating the patient healing and reducing the adverse effects of anti-microbial drugs are both desirable outcomes of adjunctive therapies (<xref rid="B22" ref-type="bibr">Hawn et&#x000a0;al., 2013</xref>; <xref rid="B45" ref-type="bibr">Tobin, 2015</xref>). Current clinical experience of anti-inflammatory therapy in TB is mostly with corticosteroids, which have been successfully used to treat tuberculous meningitis and pericarditis, as well as to ameliorate paradoxical HIV-TB immune reconstitution inflammatory syndrome (<xref rid="B35" ref-type="bibr">Prasad et&#x000a0;al., 2016</xref>; <xref rid="B26" ref-type="bibr">Kaufmann et&#x000a0;al., 2018</xref>; <xref rid="B41" ref-type="bibr">Schutz et&#x000a0;al., 2018</xref>). In pulmonary TB, the benefits of corticosteroid treatment are limited to clinical parameters, such as fever reduction and weight gain (<xref rid="B6" ref-type="bibr">Bila&#x000e7;ero&#x0011f;lu et&#x000a0;al., 1999</xref>). Thus, it would be of great interest to establish new therapeutic approaches to protect lung tissue from the harmful effects of uncontrolled inflammation caused by <italic>M. tuberculosis</italic> infection.</p><p>Our previous studies have highlighted the extracellular ATP sensing by the P2X7 receptor cation channel as a promising target candidate for host-directed therapies in severe pulmonary TB (<xref rid="B3" ref-type="bibr">Amaral et&#x000a0;al., 2014</xref>; <xref rid="B8" ref-type="bibr">Bomfim et&#x000a0;al., 2017</xref>). Although a protective role in extra pulmonary TB has been attributed to the P2X7 receptor (<xref rid="B18" ref-type="bibr">Fernando et&#x000a0;al., 2007</xref>), its effect on patients with severe pulmonary disease is unknown. ATP released at high concentrations during cell stress or death acts as a damage signal and activates the P2X7 receptor. The influx of Ca<sup>2+</sup> and efflux of K<sup>+</sup> cause cytoplasmic ionic changes, which lead to NLRP3-inflammasome activation and culminates in mature IL-1&#x003b2; and IL-18 secretion and cell death through pyroptosis (<xref rid="B31" ref-type="bibr">Mariathasan et&#x000a0;al., 2006</xref>; <xref rid="B24" ref-type="bibr">Iyer et&#x000a0;al., 2009</xref>). Importantly, prolonged stimuli of the P2X7 receptor induce necrotic cell death due to formation of large membrane pores (<xref rid="B14" ref-type="bibr">Di Virgilio et&#x000a0;al., 1989</xref>; <xref rid="B15" ref-type="bibr">Di Virgilio et&#x000a0;al., 2017</xref>). P2X7 deficiency, particularly in bone marrow-derived cells, improves lung disease in mice infected with hypervirulent mycobacteria by reducing the inflammatory response, necrotic lesions and bacterial load (<xref rid="B3" ref-type="bibr">Amaral et&#x000a0;al., 2014</xref>; <xref rid="B8" ref-type="bibr">Bomfim et&#x000a0;al., 2017</xref>). P2X7 signaling aggravates lung disease by promoting the lysis of infected macrophages, facilitating bacterial release in the extracellular milieu (<xref rid="B3" ref-type="bibr">Amaral et&#x000a0;al., 2014</xref>; <xref rid="B8" ref-type="bibr">Bomfim et&#x000a0;al., 2017</xref>). In addition, the accumulation of myeloid-derived suppressor cells in the lungs has been shown to be dependent on P2X7 activation (<xref rid="B8" ref-type="bibr">Bomfim et&#x000a0;al., 2017</xref>). This population of immature myeloid cells migrates from the bone marrow to the lungs when the disease gets worse and becomes a permissive niche for the replication of the bacillus, allowing the spread of the infection in the lungs (<xref rid="B28" ref-type="bibr">Knaul et&#x000a0;al., 2014</xref>; <xref rid="B47" ref-type="bibr">Tsiganov et&#x000a0;al., 2014</xref>; <xref rid="B30" ref-type="bibr">Lovewell et&#x000a0;al., 2020</xref>; <xref rid="B4" ref-type="bibr">Barbosa Bomfim et&#x000a0;al., 2021</xref>).</p><p>In this study, we evaluated the effects of pharmacological blockade of the P2X7 receptor on severe pulmonary TB. First, the <italic>P2RX7</italic> gene expression was assessed in the peripheral blood of TB patients using a public transcriptome database. The presence of the P2X7 receptor in lung leukocytes was evaluated in C57BL/6 mice infected with hypervirulent mycobacteria. The effects of P2X7 blockade in the advanced stage of the disease were then investigated in this experimental model of severe pulmonary TB. Our findings demonstrate that the <italic>P2RX7</italic> gene and P2X7 protein are highly expressed in human and murine TB, respectively. P2X7 inhibition prevents disease progression and is a promising approach to be used as a host-directed therapy for severe forms of pulmonary TB.</p></sec><sec sec-type="materials|methods" id="s3"><title>Materials and Methods</title><sec id="s3_1"><title>Transcriptome Analysis of Human Peripheral Blood</title><p>Human transcriptome data were analyzed using R. Raw data downloaded using <italic>GEOquery</italic> (<xref rid="B12" ref-type="bibr">Davis and Meltzer, 2007</xref>) obtained from the GEO datasets (GEO accession number: GSE54992). Two classes of samples were used: healthy donors as control (<italic>N</italic> = 6) and active TB (<italic>N</italic> = 9). Array quality control was applied using <italic>arrayQualitymetrics</italic> (<xref rid="B25" ref-type="bibr">Kauffmann et&#x000a0;al., 2009</xref>) to identify outliers. Expression data were normalized using RMA function from the <italic>affy</italic> (<xref rid="B20" ref-type="bibr">Gautier et&#x000a0;al., 2004</xref>). Probes matching for the same gene were collapsed by taking the highest expression across the samples. Differential expression analyses were performed using <italic>limma</italic> (<xref rid="B37" ref-type="bibr">Ritchie et&#x000a0;al., 2015</xref>). The differentially expressed genes (DEGs) were plotted with log<sub>2</sub> fold-change and the -log<sub>10</sub>
<italic>P</italic> adjusted value. The package <italic>ComplexHeatmap</italic> (<xref rid="B21" ref-type="bibr">Gu et&#x000a0;al., 2016</xref>) was used to plot the expression patterns.</p></sec><sec id="s3_2"><title>Mice</title><p>Specific pathogen-free C57BL/6 male (6-8-week-old) mice were bred at the isogenic mouse facility, ICB, USP. After infection, mice were maintained in micro isolator cages with <italic>ad libitum</italic> feed at the Biosafety Level 3 facility, FCF, USP. All procedures were performed in accordance with national regulations of the ethical guidelines for mouse experimentation with permit number 5611150818 and 136/2017.</p></sec><sec id="s3_3"><title>Mycobacterial Culture and Mouse Infection</title><p>The frozen bacilli were thawed and grow in Middlebrook 7H9 medium enriched with 10% (vol/vol) ADC (albumin, dextrose, catalase) (Difco, BD Biosciences, USA), 0.4% (mass/vol) sodium pyruvate (Sigma-Aldrich, USA) and 0.05% (vol/vol) Tween 80 (Sigma-Aldrich), and maintained at 37&#x000b0;C for 7 days until mid-log phase (OD 0.6 &#x02013; 0.9). Bacterial concentration was determined using a spectrophotometer at 600 nm. Mice were anesthetized intraperitoneally (i.p.) with ketamine (Vetbrands, Brazil; 100 mg/kg) and xylazine (Vetbrands; 15 mg/kg) and infected intratracheally (i.t.) with ~100 bacilli of the <italic>Mycobacterium bovis</italic> MP287/03 strain (<xref rid="B3" ref-type="bibr">Amaral et&#x000a0;al., 2014</xref>).</p></sec><sec id="s3_4"><title>Brilliant Blue G Treatment</title><p>For <italic>in vivo</italic> pharmacological blockade of the P2X7 receptor, mice were injected i.p. every 2 days with brilliant blue G (BBG, Sigma-Aldrich) (45 mg/Kg/mouse in 300 &#x000b5;L of PBS), starting on day 21 of infection.</p></sec><sec id="s3_5"><title>Lung Macroscopic and Microscopic Analyses</title><p>The harvested lung lobes were washed with sterile PBS and weighed. The lung relative mass was calculated by dividing the mean of lung weight in experimental mice by the mean of lung weight in uninfected controls. The right lung upper lobe was maintained in 10% buffer formalin, photographed and subsequently embedded in&#x000a0;paraffin. Histological sections of approximately 4-5 &#x003bc;m were stained using the hematoxylin-eosin (HE) method for tissue morphological analysis and the Ziehl Neelsen (ZN) method for mycobacterial visualization. The microscopic analyses were performed with a Leica microscope (Germany), and images were captured with a Nikon camera (Japan).</p></sec><sec id="s3_6"><title>Lung Cell Harvesting and Counting</title><p>The lung lobes were dissected and digested with collagenase type IV (0.5 mg/mL, Sigma-Aldrich) in RPMI 1640 medium (Gibco, USA) at 37&#x000b0;C for 40 minutes under agitation (200 rpm) (<xref rid="B2" ref-type="bibr">Amaral et&#x000a0;al., 2019b</xref>). The lung cells were dissociated by passage through a 100 &#x000b5;m pore-size cell strainer and incubated with ACK Lysing Buffer (Thermo Fisher Scientific, USA) at room temperature for one minute to deplete the erythrocytes. The lung cell suspensions were washed with 10% fetal calf serum (FCS, Gibco) in PBS following centrifugation at 1,200 rpm for 5 minutes and resuspended in RPMI 1640 medium enriched with 10% FCS and 0.1% gentamicin (Gibco). The viable lung cell numbers were determined using trypan blue exclusion assay and a hemocytometer.</p></sec><sec id="s3_7"><title>Flow Cytometry Analysis</title><p>Lung cells (1&#x000d7;10<sup>6</sup> cells/well) were seeded in round-bottom 96-well plates and stained using fluorochrome-labeled monoclonal antibodies to CD45 (30-F11), CD11b (M1/70), CD11c (N418), GR1 (RB6-8C5), CD4 (RM4.5), CD44 (IM7), CD69 (H1.2F3), P2X7 (1F11), lineage (CD4- RM4-5; CD8-S3-6.7; CD19 - 1D3 and NK.1 - PK136 (BD Biosciences). Live/dead dye (Thermo Fisher Scientific) was used to stain dead cells, as described in data sheet. Cells were fixed with 4% paraformaldehyde and analyzed with the LSRFortessa&#x02122; flow cytometer (BD Bioscences &#x02013; USA) and the FlowJo 10.4.2 software (BD Biosciences). The gate strategy for analysis of CD11b<sup>+</sup> myeloid cells and CD4<sup>+</sup> T cells are shown in the <xref ref-type="supplementary-material" rid="SF1">
<bold>Supplementary Figures 1A, B</bold>
</xref>.</p></sec><sec id="s3_8"><title>Colony-Forming Unit (CFU) Counting</title><p>Serial dilutions of lung homogenates were cultured in 6-well plates with Middlebrook 7H10 Agar supplemented with 10% (vol/vol) OADC (oleate, albumin, dextrose and catalase) (Difco, BD Biosciences) and 0.4% (mass/vol) sodium pyruvate, at 37&#x000b0;C for 21 days. CFUs were counted visually.</p></sec><sec id="s3_9"><title>Cytokine Quantification</title><p>Cells (1&#x000d7;10<sup>6</sup> cells/well) harvested from the lungs were cultured in sterile round-bottom 96-well plates in complete RPMI 1640 medium enriched with 10% FCS, 2 mM glutamine, 1 mM sodium pyruvate and 0.05% gentamicin for 48 hours at 37&#x000b0;C and 5% CO<sub>2.</sub> The supernatants were collected, filtered and the concentrations of TNF-&#x003b1;, IL-6, IL-10 and IFN-&#x003b3; cytokines were determined using the appropriated Mouse ELISA kit, as described in data sheet (BD OptEIA, USA).</p></sec><sec id="s3_10"><title>Statistical Analyses</title><p>Statistical analyzes were performed using the GraphPad Prism 6 software. Data were described as mean &#x000b1; standard error. The Mann-Whitney non-parametric T test was used to assess differences between two groups. The one-way ANOVA and Tukey&#x02019;s <italic>post hoc</italic> tests were used to compare three or more groups. Differences between groups were considered significant when <italic>p</italic> &#x0003c; 0.05.</p></sec></sec><sec sec-type="results" id="s4"><title>Results</title><sec id="s4_1"><title>Increased Expression of the <italic>P2RX7</italic> Gene in the Peripheral Blood of TB Patients and the P2X7 Receptor on Lung Leukocytes of Mice With Severe TB</title><p>To investigate whether the <italic>P2RX7</italic> gene was expressed differently in TB patients, we re-analyzed the peripheral blood transcriptome data from healthy individuals and patients with the active disease (<xref rid="B9" ref-type="bibr">Cai et&#x000a0;al., 2014</xref>). Among the P2X family members, only the <italic>P2RX7</italic> gene was upregulated in TB patients when compared to healthy individuals (mean log<sub>2</sub> fold-change = 1.58, adjusted <italic>P</italic> value = 1.81e-04) (<xref ref-type="fig" rid="f1">
<bold>Figure 1A</bold>
</xref>). Next, we assessed the expression of the P2X7 receptor on lung cells isolated from C57BL/6 mice infected i.t. with ~100 <italic>M. bovis</italic> bacilli of the hypervirulent MP287/03 strain. This experimental model proved to be useful to understand the role of P2X7 receptor in the development of severe forms of pulmonary TB (<xref rid="B3" ref-type="bibr">Amaral et&#x000a0;al., 2014</xref>; <xref rid="B8" ref-type="bibr">Bomfim et&#x000a0;al., 2017</xref>). As previously reported, C57BL/6 mice developed severe pneumonia characterized at day 28 p.i. by increased lung weight, high bacterial load and intense leukocyte infiltration (<xref ref-type="fig" rid="f1">
<bold>Figure 1B</bold>
</xref>), as well as extensive areas of intra-granulomatous necrosis (<xref ref-type="fig" rid="f1">
<bold>Figure 1C</bold>
</xref>). Immunofluorescence analysis of lung tissue revealed many cells expressing the P2X7 receptor in infected and uninfected mice; the expression level was apparently higher in infected mice (<xref ref-type="fig" rid="f1">
<bold>Figure 1D</bold>
</xref>). P2X7 upregulation was confirmed by flow cytometry analysis, showing higher P2X7 expression on lung leukocytes isolated from infected mice compared to uninfected mice (<xref ref-type="fig" rid="f1">
<bold>Figure 1E</bold>
</xref>). Increased P2X7 expression can make immune cells highly responsive to extracellular ATP, as previously reported in experimental models of autoimmune disease and malaria (<xref rid="B36" ref-type="bibr">Proietti et&#x000a0;al., 2014</xref>; <xref rid="B39" ref-type="bibr">Salles et&#x000a0;al., 2017</xref>).</p><fig id="f1" position="float"><label>Figure 1</label><caption><p>The expression of <italic>P2RX7</italic> gene and P2X7 receptor is increased in the peripheral blood of TB patients and on lung leukocytes of mice with severe TB. <bold>(A)</bold> Gene expression counts were z-score normalized across all samples. Log<sub>2</sub> fold-change and -log<sub>10</sub> P. adjust from DEG analysis are shown in the right annotation of the heat map. Genes were ordered by hierarchical clustering (Euclidean distance). <bold>(B&#x02013;E)</bold> C57BL/6 mice were infected i.t. with ~100 MP287/03 bacilli. Uninfected mice were used as control group. Mouse lungs were evaluated at day 28 of infection. <bold>(B)</bold> Lung weights, CFUs per lung and leukocyte (CD45<sup>+</sup>) cell numbers per lung are shown. <bold>(C)</bold> Representative lung sections stained with hematoxylin-eosin method (scale bars correspond to 500 &#x000b5;m) of infected and control group. Asterisks (*) indicate necrotic areas and hash signs (#) indicate alveolitis. <bold>(D)</bold> Immunofluorescence staining for the P2X7 receptor (green) in representative lung sections (scale bars correspond to 50 &#x000b5;m). <bold>(E)</bold> Histograms show P2X7 expression in lung leukocytes. Mean fluorescence intensities (MFIs) of P2X7 expression are shown in the bar graph. Significant differences were observed between indicated groups with *<italic>p</italic> &#x0003c; 0.05, using Mann-Whitney non-parametric T test. Data are representative of two independent experiments with three to five mice in each group.</p></caption><graphic xlink:href="fcimb-11-672472-g001"/></fig></sec><sec id="s4_2"><title>Protective Effects of P2X7 Pharmacological Blockade on the Development of Severe Pulmonary TB in Mice</title><p>To evaluate the effects of P2X7 pharmacological blockade during advanced pulmonary TB, C57BL/6 mice infected i.t. with MP287/03 mycobacteria and uninfected mice were treated i.p. with the P2X7 antagonist BBG (<xref ref-type="fig" rid="f2">
<bold>Figure 2A</bold>
</xref> and <xref ref-type="supplementary-material" rid="SF2">
<bold>Supplementary Figure 2A</bold>
</xref>). BBG is a food additive with structure and function analogous to highly selective P2X7 antagonists, which was first used to improve tissue recovery after spinal cord injury in rats (<xref rid="B34" ref-type="bibr">Peng et&#x000a0;al., 2009</xref>). P2X7-directed therapy started on day 21 p.i. when a reduction of more than 10% of body weight indicated the advanced stage of the disease (<xref ref-type="fig" rid="f2">
<bold>Figure 2B</bold>
</xref>). Notably, P2X7 inhibition prevented body weight loss until day 28 of infection. Fewer lung white nodes and reduced lung relative masses were observed in BBG-treated mice compared to untreated animals (<xref ref-type="fig" rid="f2">
<bold>Figures 2C, D</bold>
</xref>). Lung weight, cellularity and bacterial burden were also lower in BBG-treated mice (<xref ref-type="fig" rid="f2">
<bold>Figures 2E&#x02013;G</bold>
</xref>). In contrast, BBG treatment had no effect on lung weight and cellularity in uninfected mice (<xref ref-type="supplementary-material" rid="SF2">
<bold>Supplementary Figures 2B, C</bold>
</xref>).</p><fig id="f2" position="float"><label>Figure 2</label><caption><p>P2X7 pharmacological blockade at advanced pulmonary TB&#x000a0;reduces the disease severity in mice. C57BL/6 mice were infected i.t. with ~100 MP287/03 bacilli. Uninfected mice were used as control group. The P2X7 inhibitor BBG was administered i.p. at a dose of 45 mg/Kg, every 2 days, from day 21 of infection. Infected (untreated) group received the vehicle (PBS). Mouse lungs were evaluated at day 28 of infection. <bold>(A)</bold> Schematic representation of the experimental BBG treatment protocol is shown. <bold>(B)</bold> Mouse body weights were determined weekly. <bold>(C, D)</bold> Macroscopic images of representative lung lobes and relative lung masses (circles) are shown. <bold>(E&#x02013;G)</bold> Lung weights, cell numbers per lung and CFUs per lung are shown. Significant differences were observed between the indicated groups with *<italic>p</italic> &#x0003c; 0.05 and **<italic>p</italic> &#x0003c; 0.01, using One-way ANOVA and Tukey&#x02019;s <italic>post hoc</italic> tests or Mann-Whitney non-parametric T test. The statistical differences between uninfected and infected groups are not shown. Data are representative of two independent experiments with three to four mice in each group.</p></caption><graphic xlink:href="fcimb-11-672472-g002"/></fig><p>Histopathological analysis on day 28 p.i. revealed better preserved lung tissue in BBG-treated mice compared to untreated controls (<xref ref-type="fig" rid="f3">
<bold>Figure 3A</bold>
</xref>), which was corroborated by morphometric quantification of the aerated alveolar space (<xref ref-type="fig" rid="f3">
<bold>Figure 3B</bold>
</xref>). Areas of alveolitis and necrosis were substantially reduced after P2X7 inhibition (<xref ref-type="fig" rid="f3">
<bold>Figure 3A</bold>
</xref>). In addition, extracellular bacilli were found in abundance in necrotic lesions in untreated mice, but not in BBG-treated mice, where solid granulomas with predominantly intracellular bacilli were seen (<xref ref-type="fig" rid="f3">
<bold>Figure 3C</bold>
</xref>). Together, these findings demonstrate that P2X7 pharmacological blockade prevents the development of severe forms of pulmonary TB pathology in mice.</p><fig id="f3" position="float"><label>Figure 3</label><caption><p>P2X7 pharmacological blockade reduces tuberculous pulmonary lesions in mice. Histopathological changes in lungs of the BBG-treated and untreated mice, previously infected with ~100 MP287/03 bacilli, were evaluated at day 28 of infection. <bold>(A)</bold> Images of representative lung sections stained with hematoxylin-eosin method (scale bars correspond to 200 &#x000b5;m) are shown. Asterisks (*) indicate necrotic areas and hash signs (#) indicate alveolitis. <bold>(B)</bold> Morphometric quantification of aerated alveolar space is shown. <bold>(C)</bold> Images of representative lung sections stained with Ziehl Neelsen method. Magnified areas from left squares are demonstrated in right images (scale bars correspond to 100 &#x000b5;m and 25 &#x000b5;m, respectively), showing large number of extracellular bacilli in necrotic regions (*) in untreated mice, whereas predominantly intracellular bacilli were seen in the BBG-treated mice. Significant differences were observed between indicated groups with *<italic>p</italic> &#x0003c; 0.05, using Mann-Whitney non-parametric T test. Data are representative of two independent experiments with four mice in each group.</p></caption><graphic xlink:href="fcimb-11-672472-g003"/></fig></sec><sec id="s4_3"><title>Reduced Leukocyte Recruitment in Mice With Advanced TB Treated With P2X7-Directed Therapy</title><p>The pulmonary immune response was then assessed in C57BL/6 mice infected with MP287/03 mycobacteria and treated with BBG. P2X7-directed therapy caused a substantial reduction in the recruitment of leukocyte (CD45<sup>+</sup>) population to the lungs (<xref ref-type="fig" rid="f4">
<bold>Figure 4A</bold>
</xref>). Among CD11b<sup>+</sup> myeloid cells, the GR1<sup>+</sup> population was particularly diminished after P2X7 blockade. Notably, the population of myeloid cells expressing CD11c was increased in BBG-treated mice compared to untreated animals. Regarding CD4<sup>+</sup> T cells, P2X7-directed therapy impaired the accumulation of total and CD69<sup>+</sup>CD44<sup>+</sup> populations (<xref ref-type="fig" rid="f4">
<bold>Figure 4B</bold>
</xref>). This phenotype is characteristic of effector CD4<sup>+</sup> T cells that infiltrate the pulmonary parenchyma in mice infected with mycobacteria (<xref rid="B38" ref-type="bibr">Sakai et&#x000a0;al., 2014</xref>). In the absence of infection, similar numbers of these cell populations were observed in BBG-treated and untreated mice (<xref ref-type="supplementary-material" rid="SF2">
<bold>Supplementary Figures 2D, E</bold>
</xref>). In addition, a lower concentration of TNF-&#x003b1; was found in lung cell supernatants from infected mice treated with BBG compared to those not treated (<xref ref-type="fig" rid="f4">
<bold>Figure 4C</bold>
</xref>). Remarkably, low levels of IFN-&#x003b3; and IL-6 were secreted by lung cells from infected mice; BBG treatment increased substantially the production of these cytokines. IL-10 was produced at similar levels by lung cells from both infected mouse groups. Comparable baseline levels of TNF-&#x003b1;, IL-6, IFN-&#x003b3; and IL-10 were found in lung cell supernatants from uninfected mice, treated or not with BBG (<xref ref-type="supplementary-material" rid="SF2">
<bold>Supplementary Figure 2F</bold>
</xref>).</p><fig id="f4" position="float"><label>Figure 4</label><caption><p>P2X7-directed therapy reduces the pulmonary inflammatory response, but increases the population of CD11c<sup>+</sup> myeloid cells and the production of IFN-&#x003b3; and IL-6 by lung cells. Lung cells from BBG-treated and untreated mice were evaluated at day 28 p.i. with ~100 MP287/03 bacilli. Lung cells from uninfected mice were used as control. <bold>(A)</bold> Contour-plots show the expression of CD11b <italic>vs</italic> lineage in CD45<sup>+</sup> cells and CD11c <italic>vs</italic> GR-1 in CD11b<sup>+</sup>CD45<sup>+</sup> cells. Bar graphs show cell numbers per lung. <bold>(B)</bold> Contour-plots show CD44 and CD69 expression in CD4<sup>+</sup> T cells. Bar graphs show cell numbers per lung. <bold>(C)</bold> Cytokine levels in 48h-culture supernatants of lung cells are shown. Significant differences were observed between the indicated groups with *<italic>p</italic> &#x0003c; 0.05, **<italic>p</italic> &#x0003c; 0.01 and ***<italic>p</italic> &#x0003c; 0.001, using One-way ANOVA and Tukey&#x02019;s <italic>post hoc</italic> tests. The statistical differences between uninfected and infected groups are not shown. Data are representative of two independent experiments with three to four mice in each group.</p></caption><graphic xlink:href="fcimb-11-672472-g004"/></fig><p>In resume, P2X7-directed therapy during advanced TB impairs the recruitment of GR1<sup>+</sup> myeloid cells and CD4<sup>+</sup> T cells to the lungs (<xref ref-type="fig" rid="f5">
<bold>Figure 5</bold>
</xref>). The increase in a myeloid cell population with characteristics of dendritic cells, as well as in production of IFN-&#x003b3; and IL-6 by lung cells, suggests a qualitative improvement in the pulmonary immune response due to P2X7 inhibition.</p><fig id="f5" position="float"><label>Figure 5</label><caption><p>Schematic illustration shows the effects of P2X7-directed therapy on the pulmonary inflammatory response to hypervirulent mycobacterial infection. P2X7-mediated necrotic death of lung leukocytes promote bacillus spread and ATP release to the extracellular milieu. Extracellular ATP at high concentration stimulates the P2X7 receptor and exacerbates inflammatory and necrotic lung lesions. The P2X7-direct therapy reduces the recruitment of lung leukocytes, particularly neutrophils (GR1<sup>+</sup>CD11b<sup>+</sup>), as well as the production of TNF-&#x003b1;. The effector CD4<sup>+</sup> T cell population was also decreased, but IFN-&#x003b3; production by lung cells was increased. P2X7 inhibition also increases the population of myeloid dendritic cells (CD11c<sup>+</sup>CD11b<sup>+</sup>) and the production of IL-6 by lung cells, indicating a qualitative improvement in the pulmonary immune response. This scenario supports the use of therapeutic interventions in the P2X7 receptor to increase the effectiveness of anti-microbial treatment and reduce the severity of pulmonary TB.</p></caption><graphic xlink:href="fcimb-11-672472-g005"/></fig></sec></sec><sec sec-type="discussion" id="s5"><title>Discussion</title><p>This study supports the use of drugs that target the P2X7 receptor as a therapeutic strategy to improve the outcome of pulmonary TB. This approach can be particularly useful, in combination with anti-microbial drugs, to interrupt the vicious cycle of uncontrolled inflammatory response and damage to lung tissue in severe forms of the disease.</p><p>Among P2X (1-7) family members, the <italic>P2RX7</italic> gene expression was the only one increased in peripheral blood of TB patients in relation to healthy donors. Another indication that P2X7 signaling is a promising target for host-directed therapies in pulmonary TB was the increased expression of this receptor in lung leukocytes of mice infected with hypervirulent mycobacteria. Extracellular ATP at high concentration in severe TB pneumonia could lead to strong activation of the NLRP3 inflammasome in leukocytes expressing high levels of the P2X7 receptor. The release of large amounts of pro-inflammatory cytokines and the pyroptotic death of numerous immune cells would be expected in this scenario. In addition, both gasdermin D cleaved by caspase-1 and pannexin-1 activated by the influx of Ca<sup>2+</sup> form pores in the cell membrane, allowing ATP release in the extracellular environment (<xref rid="B29" ref-type="bibr">Locovei et&#x000a0;al., 2006</xref>; <xref rid="B44" ref-type="bibr">Shi et&#x000a0;al., 2015</xref>; <xref rid="B40" ref-type="bibr">Sborgi et&#x000a0;al., 2016</xref>). Accumulation of extracellular ATP may boost the inflammatory response and promote tissue damage. Extracellular ATP in millimolar concentrations induces pore formation and necrotic cell death through P2X7 activation (<xref rid="B14" ref-type="bibr">Di Virgilio et&#x000a0;al., 1989</xref>; <xref rid="B15" ref-type="bibr">Di Virgilio et&#x000a0;al., 2017</xref>). By inhibiting the P2X7 signaling pathway these processes can be interrupted.</p><p>P2X7 pharmacological blockade in mice with advanced pulmonary TB recapitulated in many aspects the disease in P2X7-deficient mice infected with hypervirulent mycobacteria (<xref rid="B3" ref-type="bibr">Amaral et&#x000a0;al., 2014</xref>). P2X7-directed therapy administered over a short period of time was effective in reducing body weight loss and the development of inflammatory and necrotic lung lesions, as well as delaying mycobacterial growth. The reduction in body weight loss in infected mice treated with P2X7 inhibitor may result from the lower production of TNF-&#x003b1; by lung leukocytes, as this cytokine was originally identified by its ability to induce cachexia (<xref rid="B11" ref-type="bibr">Cerami and Beutler, 1988</xref>). The decrease in pulmonary necrotic lesions may be due to the inhibition of necrotic cell death, as a consequence of P2X7 signaling blockade. Specifically, <italic>P2RX7</italic>
<sup>-/-</sup> macrophages infected with hypervirulent mycobacteria are more resistant to cell death induced by high levels of extracellular ATP and release fewer bacteria to the extracellular milieu than wild-type macrophages (<xref rid="B3" ref-type="bibr">Amaral et&#x000a0;al., 2014</xref>). Supporting this <italic>in vitro</italic> finding, fewer extracellular bacilli were found in the lung tissue when the P2X7 receptor was inhibited <italic>in vivo</italic>.</p><p>The reduction in tissue damage and bacterial load, leading to less stimulation of the immune system by damage and pathogen-associated molecular patterns, may explain the limited areas of lung inflammation in infected mice given the P2X7-directed therapy. A similar approach in which ferroptosis was inhibited in mice acutely infected with <italic>M. tuberculosis</italic> also reduces lung inflammatory lesions and mycobacterial burden (<xref rid="B1" ref-type="bibr">Amaral et&#x000a0;al., 2019a</xref>). P2X7 signaling blockade may reduce the release of damage signals, impairing the activation of macrophages and, consequently, the secretion of pro-inflammatory cytokines, such as TNF-&#x003b1;. P2X7 inhibition may also restrain the activation of NLRP3 inflammasome and the release of mature IL-1&#x003b2; and IL-18, promoting control of the inflammatory response. However, on day 28 p.i. with MP287/03 mycobacteria, IL-1&#x003b2; is produced at low levels by lung cells from both C57BL/6 and P2X7-deficient mice (<xref rid="B3" ref-type="bibr">Amaral et&#x000a0;al., 2014</xref>), suggesting a minor role for this cytokine in this TB model. A direct effect of P2X7 inhibition on Ca<sup>2+</sup> influx may also have impaired leukocyte activation and contributed to restrict the inflammatory response. Supporting this idea, P2X7 signaling in myeloid cells induces the expression of several chemokines that promote leukocyte recruitment, such as monocyte chemoattractant protein 1 (MCP-1, CCL2), IL-8, CC-ligand 3 (CCL3) and CXC-ligand 2 (CXCL2), as well as the production of pro-inflammatory cytokines, such as TNF-&#x003b1; (<xref rid="B43" ref-type="bibr">Shieh et&#x000a0;al., 2014</xref>; <xref rid="B15" ref-type="bibr">Di Virgilio et&#x000a0;al., 2017</xref>). A reduction in TNF-&#x003b1; production due to P2X7 blockade may also have contributed to restrain necrotic lung lesions, as excessive production of this cytokine can result in the development of tissue-damaging immunopathology (<xref rid="B16" ref-type="bibr">Dorhoi and Kaufmann, 2014</xref>).</p><p>The population of GR-1<sup>+</sup> myeloid cells was particularly affected by P2X7 pharmacological blockade. Characterized as granulocytic myeloid-derived suppressor cells, GR-1<sup>+</sup> cells accumulate massively in the lungs during the final stage of hypervirulent mycobacterial infection, promoting bacterial growth and the development of necrotizing pneumonia (<xref rid="B4" ref-type="bibr">Barbosa Bomfim et&#x000a0;al., 2021</xref>). This immature myeloid cell population is generated by emergency hematopoiesis in response to excessive or chronic infections (<xref rid="B7" ref-type="bibr">Boettcher and Manz, 2017</xref>). Therefore, the reduction in the GR-1<sup>+</sup> cell population demonstrates the potential of P2X7-directed therapy to help healing severe pulmonary TB. The effector CD4<sup>+</sup> T cell population also decreased due to P2X7 inhibition. Interestingly, elevated production of IFN-&#x003b3; was found <italic>ex vivo</italic> in lung cell suspension of mice receiving BBG, suggesting an improvement in the effector response of these cells and/or an increase in IFN-&#x003b3; production by other cell subsets.</p><p>Adenosine, presumably generated through ATP degradation by ectonucleotidases, has been implicated in the suppression of IFN-&#x003b3; production by lung CD4<sup>+</sup> T cells in this experimental model of severe TB. The pharmacological inhibition of adenosine receptors increased the frequency of IFN-&#x003b3;-producing CD4<sup>+</sup> T cells (<xref rid="B2" ref-type="bibr">Amaral et&#x000a0;al., 2019b</xref>), which are the major source of IFN-&#x003b3; in the lungs of MP287/03-infected mice at day 28 p.i. (<xref rid="B4" ref-type="bibr">Barbosa Bomfim et&#x000a0;al., 2021</xref>). The protection of infected lung tissue resulting from P2X7 inhibition may prevent ATP release and, consequently, the accumulation of adenosine in the extracellular environment, leading to an increase in IFN-&#x003b3; production by CD4<sup>+</sup> T cells. IFN-&#x003b3; production has a crucial role in resistance to <italic>M. tuberculosis</italic> infection (<xref rid="B19" ref-type="bibr">Flynn et&#x000a0;al., 1993</xref>), and may have contributed to control the lung bacterial burden in infected mice treated with P2X7-directed therapy. The presence of a large population with characteristics of myeloid dendritic cells in the mouse lungs (<xref rid="B33" ref-type="bibr">Misharin et&#x000a0;al., 2013</xref>), as well as the increased <italic>ex vivo</italic> production of IL-6 by lung cells, may also indicate a qualitative improvement in the pulmonary immune response due to P2X7 inhibition. Our interpretation of these findings is that the preservation of lung tissue due to P2X7 blockade in infected mice allowed the recruitment of dendritic cells from the blood to the lungs. This process occurs constantly by a steady-state bone marrow output and is rapidly intensified by pathogenic stimuli (<xref rid="B23" ref-type="bibr">Holt and Schon-Hegrad, 1987</xref>; <xref rid="B32" ref-type="bibr">McWilliam et&#x000a0;al., 1994</xref>). Dendritic cell migration to the lungs may have been interrupted during emergency hematopoiesis in infected and untreated mice. Like macrophages, pulmonary dendritic cells produce IL-6 after stimulation (<xref rid="B13" ref-type="bibr">Demedts et&#x000a0;al., 2005</xref>), and are presumably an important source of this cytokine in infected mice given P2X7-directed therapy.</p><p>Although the P2X7 receptor has been suggested previously as a promising target candidate for therapies in severe pulmonary TB (<xref rid="B3" ref-type="bibr">Amaral et&#x000a0;al., 2014</xref>), our present findings provide proof of concept for this approach in mice infected with hypervirulent mycobacteria. The P2X7-directed therapy has the particularity of intervening directly to maintain the integrity of the infected lungs, avoiding the uncontrolled inflammatory response induced by extensive tissue damage. In addition, therapeutic intervention in the P2X7 receptor seems to improve the quality of the immune response to severe mycobacterial infection. A possible adverse effect of P2X7 inhibition would be the increase in mycobacterial resistance to anti-TB treatment, resulting from the limited effect of antibiotics on bacilli located in solid granulomas. However, this host-directed therapy can be decisive for a favorable outcome in severe cases if administered in conjunction with anti-TB drugs with ability to eradicate persistent bacilli, such as pyrazinamide (<xref rid="B48" ref-type="bibr">Whitfield et&#x000a0;al., 2015</xref>). This therapeutic strategy can be exploited to increase the effectiveness of anti-TB treatment in severe pulmonary TB.</p></sec><sec sec-type="data-availability" id="s6"><title>Data Availability Statement</title><p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SF1">
<bold>Supplementary Material</bold>
</xref>. Further inquiries can be directed to the corresponding authors.</p></sec><sec id="s7"><title>Ethics Statement</title><p>The animal study was reviewed and approved by Animal Care Committee of Institute of Biomedical Science with permit number 5611150818 and 136/2017.</p></sec><sec id="s8"><title>Author Contributions </title><p>Conceived and designed the experiments: IS-C; GA-S; CCBB; HI and MRDL. Performed the experiments: IS-C; GA-S; CCBB; PCS; BS and MP. Analyzed the data: IS-C; GA-S; CCBB; JCSS and MRDL. Contributed reagents/materials/analysis tools: IS-C; GA-S; CB; EPA; MHH; EL; JCFA-F; HIN; JMA and MRDL.</p></sec><sec sec-type="funding-information" id="s9"><title>Funding</title><p>This study was supported in whole by S&#x000e3;o Paulo Research Foundation (FAPESP-Brazil) grants: 2015/20432-8 (MRDL), 2019/24700-8 (IS-C), 2017/11030-9 (PCS), 2019/27139-5 (JCSS) and 2020/09043-8 (CCBB); and by National Council for Scientific and Technological Development (CNPq) grants: 408909/2018-8 (MRDL), 303810/2018-1 (MRDL) and 140666/2018-4 (GA-S). All authors contributed to the article and approved the submitted version.</p></sec><sec sec-type="COI-statement" id="s10"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank Jos&#x000e9; Soares Ferreira Neto for providing the MP287/03 <italic>M. bovis</italic> strain. We are also grateful to Rog&#x000e9;rio Silva do Nascimento, Jos&#x000e9; Israel Lima, Silvana Silva and Maria &#x000c1;urea de Alvarenga for technical assistance.</p></ack><sec id="s11" sec-type="supplementary-material"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fcimb.2021.672472/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fcimb.2021.672472/full#supplementary-material</ext-link></p><supplementary-material content-type="local-data" id="SF1"><label>Supplementary Figure 1</label><caption><p>Gate strategies for the analyses of myeloid cells and CD4<sup>+</sup> T cells are shown in mice infected with MP287/03 mycobacteria, treated or not treated with BBG. C57BL/6 mice were infected i.t. with ~100 MP287/03 bacilli. Lung cells were evaluated at day 28 of infection. <bold>(A)</bold> Gate strategies to evaluate CD45<sup>+</sup>, CD45<sup>+</sup>Lin<sup>-</sup>CD11b<sup>+</sup>, CD45<sup>+</sup>Lin<sup>-</sup>CD11b<sup>+</sup>CD11c<sup>+</sup>, CD45<sup>+</sup>Lin<sup>-</sup>CD11b<sup>+</sup>GR1<sup>+</sup> cells are shown. <bold>(B)</bold> Gate strategies to evaluate CD4<sup>+</sup> T cells and CD69<sup>+</sup>CD44<sup>+</sup>CD4<sup>+</sup> T cells are shown.</p></caption><media xlink:href="Image_1.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SF2"><label>Supplementary Figure 2</label><caption><p>BBG treatment does not interfere with pulmonary immunological parameters in uninfected C57BL/6 mice. Four doses of BBG (45 mg/kg) were administered i.p. every two days in C57BL/6 mice, and lung cells were harvested 7 days after the first dose. Untreated C57BL/6 mice were used as controls. <bold>(A)</bold> Schematic representation of the experimental BBG treatment protocol is shown. <bold>(B)</bold> Lung weights are shown. <bold>(C)</bold> Cell numbers per lung are shown. <bold>(D)</bold> CD45<sup>+</sup>, CD11b<sup>+</sup>CD45<sup>+</sup> and CD11c<sup>+</sup>CD11b<sup>+</sup>CD45<sup>+</sup>, GR1<sup>+</sup>CD11b<sup>+</sup>CD45<sup>+</sup> cell numbers per lung are shown. <bold>(E)</bold> CD4<sup>+</sup> and CD69<sup>+</sup>CD44<sup>+</sup>CD4<sup>+</sup> T cell numbers per lung are shown. <bold>(F)</bold> Cytokine levels in 48h-culture supernatants of lung cells are shown. No significant difference was observed using Mann-Whitney non-parametric T test.</p></caption><media xlink:href="Image_2.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amaral</surname><given-names>E. P.</given-names></name><name><surname>Costa</surname><given-names>D. L.</given-names></name><name><surname>Namasivayam</surname><given-names>S.</given-names></name><name><surname>Riteau</surname><given-names>N.</given-names></name><name><surname>Kamenyeva</surname><given-names>O.</given-names></name><name><surname>Mittereder</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2019</year>a). <article-title>A Major Role for Ferroptosis in Mycobacterium Tuberculosis-Induced Cell Death and Tissue Necrosis</article-title>. <source>J. Exp. Med.</source>
<volume>216</volume> (<issue>3</issue>), <fpage>556</fpage>&#x02013;<lpage>570</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1084/jem.20181776</pub-id>
<pub-id pub-id-type="pmid">30787033</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amaral</surname><given-names>E. P.</given-names></name><name><surname>Machado de Salles</surname><given-names>E.</given-names></name><name><surname>Barbosa Bomfim</surname><given-names>C. C.</given-names></name><name><surname>Salgado</surname><given-names>R. M.</given-names></name><name><surname>Almeida</surname><given-names>F. M.</given-names></name><name><surname>de Souza</surname><given-names>P. C.</given-names></name><etal/></person-group>. (<year>2019</year>b). <article-title>Inhibiting Adenosine Receptor Signaling Promotes Accumulation of Effector CD4+ T Cells in the Lung Parenchyma During Severe Tuberculosis</article-title>. <source>J. Infect. Dis.</source>
<volume>219</volume> (<issue>6</issue>), <fpage>964</fpage>&#x02013;<lpage>974</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1093/infdis/jiy586</pub-id>
<pub-id pub-id-type="pmid">30307561</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amaral</surname><given-names>E. P.</given-names></name><name><surname>Ribeiro</surname><given-names>S. C.</given-names></name><name><surname>Lanes</surname><given-names>V. R.</given-names></name><name><surname>Almeida</surname><given-names>F. M.</given-names></name><name><surname>de Andrade</surname><given-names>M. R.</given-names></name><name><surname>Bomfim</surname><given-names>C. C.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Pulmonary Infection With Hypervirulent Mycobacteria Reveals a Crucial Role for the P2X7 Receptor in Aggressive Forms of Tuberculosis</article-title>. <source>PloS Pathog.</source>
<volume>10</volume> (<issue>7</issue>). <pub-id pub-id-type="doi">10.1371/journal.ppat.1004188</pub-id>
</mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barbosa Bomfim</surname><given-names>C. C.</given-names></name><name><surname>Pinheiro Amaral</surname><given-names>E.</given-names></name><name><surname>Santiago-Carvalho</surname><given-names>I.</given-names></name><name><surname>Almeida Santos</surname><given-names>G.</given-names></name><name><surname>Machado Salles</surname><given-names>&#x000c9;.</given-names></name><name><surname>Hastreiter</surname><given-names>A. A.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Harmful Effects of Granulocytic Myeloid-Derived Suppressor Cells on Tuberculosis Caused by Hypervirulent Mycobacteria</article-title>. <source>J. Infect. Dis.</source>
<volume>223</volume> (<issue>3</issue>), <fpage>494</fpage>&#x02013;<lpage>507</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1093/infdis/jiaa708</pub-id>
<pub-id pub-id-type="pmid">33206171</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bell</surname><given-names>L. C. K.</given-names></name><name><surname>Noursadeghi</surname><given-names>M.</given-names></name></person-group> (<year>2018</year>). <article-title>Pathogenesis of HIV-1 and Mycobacterium Tuberculosis Co-Infection</article-title>. <source>Nat. Rev. Microbiol.</source>
<volume>16</volume> (<issue>2</issue>), <fpage>80</fpage>&#x02013;<lpage>90</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1038/nrmicro.2017.128</pub-id>
<pub-id pub-id-type="pmid">29109555</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bila&#x000e7;ero&#x0011f;lu</surname><given-names>S.</given-names></name><name><surname>Perim</surname><given-names>K.</given-names></name><name><surname>B&#x000fc;y&#x000fc;k&#x0015f;irin</surname><given-names>M.</given-names></name><name><surname>Celikten</surname><given-names>E.</given-names></name></person-group> (<year>1999</year>). <article-title>Prednisolone: A Beneficial and Safe Adjunct to Antituberculosis Treatment? A Randomized Controlled Trial</article-title>. <source>Int. J. Tuberc Lung Dis.</source>
<volume>3</volume> (<issue>1</issue>), <fpage>47</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">10094169</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boettcher</surname><given-names>S.</given-names></name><name><surname>Manz</surname><given-names>M. G.</given-names></name></person-group> (<year>2017</year>). <article-title>Regulation of Inflammation- and Infection-Driven Hematopoiesis</article-title>. <source>Trends Immunol.</source>
<volume>38</volume> (<issue>5</issue>), <fpage>345</fpage>&#x02013;<lpage>357</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1016/j.it.2017.01.004</pub-id>
<pub-id pub-id-type="pmid">28216309</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bomfim</surname><given-names>C. C. B.</given-names></name><name><surname>Amaral</surname><given-names>E. P.</given-names></name><name><surname>Cassado</surname><given-names>A. D. A.</given-names></name><name><surname>Salles</surname><given-names>E. M.</given-names></name><name><surname>do Nascimento</surname><given-names>R. S.</given-names></name><name><surname>Lasunskaia</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>P2X7 Receptor in Bone Marrow-Derived Cells Aggravates Tuberculosis Caused by Hypervirulent Mycobacterium Bovis</article-title>. <source>Front. Immunol.</source>
<volume>8</volume>, <elocation-id>435</elocation-id>. &#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2017.00435</pub-id>
<pub-id pub-id-type="pmid">28450867</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cai</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Q.</given-names></name><name><surname>Tang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Increased Complement C1q Level Marks Active Disease in Human Tuberculosis</article-title>. <source>PloS One</source>
<volume>9</volume> (<issue>3</issue>), <fpage>e92340</fpage>. &#x000a0;<pub-id pub-id-type="doi">10.1371/journal.pone.0092340</pub-id>
<pub-id pub-id-type="pmid">24647646</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Caws</surname><given-names>M.</given-names></name><name><surname>Thwaites</surname><given-names>G.</given-names></name><name><surname>Dunstan</surname><given-names>S.</given-names></name><name><surname>Hawn</surname><given-names>T. R.</given-names></name><name><surname>Lan</surname><given-names>N. T.</given-names></name><name><surname>Thuong</surname><given-names>N. T.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>The Influence of Host and Bacterial Genotype on the Development of Disseminated Disease With Mycobacterium Tuberculosis</article-title>. <source>PloS Pathog.</source>
<volume>4</volume> (<issue>3</issue>), <fpage>e1000034</fpage>. &#x000a0;<pub-id pub-id-type="doi">10.1371/journal.ppat.1000034</pub-id>
<pub-id pub-id-type="pmid">18369480</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cerami</surname><given-names>A.</given-names></name><name><surname>Beutler</surname><given-names>B.</given-names></name></person-group> (<year>1988</year>). <article-title>The Role of Cachectin/TNF in Endotoxic Shock and Cachexia</article-title>. <source>Immunol. Today</source>
<volume>9</volume> (<issue>1</issue>), <fpage>28</fpage>&#x02013;<lpage>31</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1016/0167-5699(88)91353-9</pub-id>
<pub-id pub-id-type="pmid">3076757</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davis</surname><given-names>S.</given-names></name><name><surname>Meltzer</surname><given-names>P. S.</given-names></name></person-group> (<year>2007</year>). <article-title>GEOquery: A Bridge Between the Gene Expression Omnibus (GEO) and Bioconductor</article-title>. <source>Bioinformatics</source>
<volume>23</volume> (<issue>14</issue>), <fpage>1846</fpage>&#x02013;<lpage>1847</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1093/bioinformatics/btm254</pub-id>
<pub-id pub-id-type="pmid">17496320</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Demedts</surname><given-names>I. K.</given-names></name><name><surname>Brusselle</surname><given-names>G. G.</given-names></name><name><surname>Vermaelen</surname><given-names>K. Y.</given-names></name><name><surname>Pauwels</surname><given-names>R. A.</given-names></name></person-group> (<year>2005</year>). <article-title>Identification and Characterization of Human Pulmonary Dendritic Cells</article-title>. <source>Am. J. Respir. Cell Mol. Biol.</source>
<volume>32</volume> (<issue>3</issue>), <fpage>177</fpage>&#x02013;<lpage>184</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1165/rcmb.2004-0279OC</pub-id>
<pub-id pub-id-type="pmid">15576669</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Di Virgilio</surname><given-names>F.</given-names></name><name><surname>Bronte</surname><given-names>V.</given-names></name><name><surname>Collavo</surname><given-names>D.</given-names></name><name><surname>Zanovello</surname><given-names>P.</given-names></name></person-group> (<year>1989</year>). <article-title>Responses of Mouse Lymphocytes to Extracellular Adenosine 5&#x02019;-Triphosphate (ATP). Lymphocytes With Cytotoxic Activity are Resistant to the Permeabilizing Effects of ATP</article-title>. <source>J. Immunol.</source>
<volume>143</volume> (<issue>6</issue>), <fpage>1955</fpage>&#x02013;<lpage>1960</lpage>.<pub-id pub-id-type="pmid">2789252</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Di Virgilio</surname><given-names>F.</given-names></name><name><surname>Dal Ben</surname><given-names>D.</given-names></name><name><surname>Sarti</surname><given-names>A. C.</given-names></name><name><surname>Giuliani</surname><given-names>A. L.</given-names></name><name><surname>Falzoni</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>The P2X7 Receptor in Infection and Inflammation</article-title>. <source>Immunity</source>
<volume>47</volume> (<issue>1</issue>), <fpage>15</fpage>&#x02013;<lpage>31</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1016/j.immuni.2017.06.020</pub-id>
<pub-id pub-id-type="pmid">28723547</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dorhoi</surname><given-names>A.</given-names></name><name><surname>Kaufmann</surname><given-names>S. H.</given-names></name></person-group> (<year>2014</year>). <article-title>Tumor Necrosis Factor Alpha in Mycobacterial Infection</article-title>. <source>Semin. Immunol.</source>
<volume>26</volume> (<issue>3</issue>), <fpage>203</fpage>&#x02013;<lpage>209</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1016/j.smim.2014.04.003</pub-id>
<pub-id pub-id-type="pmid">24819298</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ernst</surname><given-names>J. D.</given-names></name></person-group> (<year>2018</year>). <article-title>Mechanisms of M.&#x000a0;tuberculosis Immune Evasion as Challenges to TB Vaccine Design</article-title>. <source>Cell Host Microbe</source>
<volume>24</volume> (<issue>1</issue>), <fpage>34</fpage>&#x02013;<lpage>42</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1016/j.chom.2018.06.004</pub-id>
<pub-id pub-id-type="pmid">30001523</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fernando</surname><given-names>S. L.</given-names></name><name><surname>Saunders</surname><given-names>B. M.</given-names></name><name><surname>Sluyter</surname><given-names>R.</given-names></name><name><surname>Skarratt</surname><given-names>K. K.</given-names></name><name><surname>Goldberg</surname><given-names>H.</given-names></name><name><surname>Marks</surname><given-names>G. B.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>A Polymorphism in the P2X(7) Gene Increases Susceptibility to Extrapulmonary Tuberculosis</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>175</volume> (<issue>4</issue>), <fpage>360</fpage>&#x02013;<lpage>366</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1164/rccm.200607-970OC</pub-id>
<pub-id pub-id-type="pmid">17095747</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Flynn</surname><given-names>J. L.</given-names></name><name><surname>Chan</surname><given-names>J.</given-names></name><name><surname>Triebold</surname><given-names>K. J.</given-names></name><name><surname>Dalton</surname><given-names>D. K.</given-names></name><name><surname>Stewart</surname><given-names>T. A.</given-names></name><name><surname>Bloom</surname><given-names>B. R.</given-names></name></person-group> (<year>1993</year>). <article-title>An Essential Role for Interferon Gamma in Resistance to Mycobacterium Tuberculosis Infection</article-title>. <source>J. Exp. Med.</source>
<volume>178</volume> (<issue>6</issue>), <fpage>2249</fpage>&#x02013;<lpage>2254</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1084/jem.178.6.2249</pub-id>
<pub-id pub-id-type="pmid">7504064</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gautier</surname><given-names>L.</given-names></name><name><surname>Cope</surname><given-names>L.</given-names></name><name><surname>Bolstad</surname><given-names>B. M.</given-names></name><name><surname>Irizarry</surname><given-names>R. A.</given-names></name></person-group> (<year>2004</year>). <article-title>Affy&#x02013;Analysis of Affymetrix GeneChip Data At the Probe Level</article-title>. <source>Bioinformatics</source>
<volume>20</volume> (<issue>3</issue>), <fpage>307</fpage>&#x02013;<lpage>315</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1093/bioinformatics/btg405</pub-id>
<pub-id pub-id-type="pmid">14960456</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gu</surname><given-names>Z.</given-names></name><name><surname>Eils</surname><given-names>R.</given-names></name><name><surname>Schlesner</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Complex Heatmaps Reveal Patterns and Correlations in Multidimensional Genomic Data</article-title>. <source>Bioinformatics</source>
<volume>32</volume> (<issue>18</issue>), <fpage>2847</fpage>&#x02013;<lpage>2849</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1093/bioinformatics/btw313</pub-id>
<pub-id pub-id-type="pmid">27207943</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hawn</surname><given-names>T. R.</given-names></name><name><surname>Matheson</surname><given-names>A. I.</given-names></name><name><surname>Maley</surname><given-names>S. N.</given-names></name><name><surname>Vandal</surname><given-names>O.</given-names></name></person-group> (<year>2013</year>). <article-title>Host-Directed Therapeutics for Tuberculosis: can We Harness the Host</article-title>? <source>Microbiol. Mol. Biol. Rev.</source>
<volume>77</volume> (<issue>4</issue>), <fpage>608</fpage>&#x02013;<lpage>627</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1128/mmbr.00032-13</pub-id>
<pub-id pub-id-type="pmid">24296574</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Holt</surname><given-names>P. G.</given-names></name><name><surname>Schon-Hegrad</surname><given-names>M. A.</given-names></name></person-group> (<year>1987</year>). <article-title>Localization of T Cells, Macrophages and Dendritic Cells in Rat Respiratory Tract Tissue: Implications for Immune Function Studies</article-title>. <source>Immunology</source>
<volume>62</volume> (<issue>3</issue>), <fpage>349</fpage>&#x02013;<lpage>356</lpage>.<pub-id pub-id-type="pmid">3499375</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iyer</surname><given-names>S. S.</given-names></name><name><surname>Pulskens</surname><given-names>W. P.</given-names></name><name><surname>Sadler</surname><given-names>J. J.</given-names></name><name><surname>Butter</surname><given-names>L. M.</given-names></name><name><surname>Teske</surname><given-names>G. J.</given-names></name><name><surname>Ulland</surname><given-names>T. K.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Necrotic Cells Trigger a Sterile Inflammatory Response Through the Nlrp3 Inflammasome</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<volume>106</volume> (<issue>48</issue>), <fpage>20388</fpage>&#x02013;<lpage>20393</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0908698106</pub-id>
<pub-id pub-id-type="pmid">19918053</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kauffmann</surname><given-names>A.</given-names></name><name><surname>Gentleman</surname><given-names>R.</given-names></name><name><surname>Huber</surname><given-names>W.</given-names></name></person-group> (<year>2009</year>). <article-title>arrayQualityMetrics&#x02013;A Bioconductor Package for Quality Assessment of Microarray Data</article-title>. <source>Bioinformatics</source>
<volume>25</volume> (<issue>3</issue>), <fpage>415</fpage>&#x02013;<lpage>416</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1093/bioinformatics/btn647</pub-id>
<pub-id pub-id-type="pmid">19106121</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>S. H. E.</given-names></name><name><surname>Dorhoi</surname><given-names>A.</given-names></name><name><surname>Hotchkiss</surname><given-names>R. S.</given-names></name><name><surname>Bartenschlager</surname><given-names>R.</given-names></name></person-group> (<year>2018</year>). <article-title>Host-Directed Therapies for Bacterial and Viral Infections</article-title>. <source>Nat. Rev. Drug Discov.</source>
<volume>17</volume> (<issue>1</issue>), <fpage>35</fpage>&#x02013;<lpage>56</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1038/nrd.2017.162</pub-id>
<pub-id pub-id-type="pmid">28935918</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>S. H.</given-names></name><name><surname>Lange</surname><given-names>C.</given-names></name><name><surname>Rao</surname><given-names>M.</given-names></name><name><surname>Balaji</surname><given-names>K. N.</given-names></name><name><surname>Lotze</surname><given-names>M.</given-names></name><name><surname>Schito</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Progress in Tuberculosis Vaccine Development and Host-Directed Therapies&#x02013;A State of the Art Review</article-title>. <source>Lancet Respir. Med.</source>
<volume>2</volume> (<issue>4</issue>), <fpage>301</fpage>&#x02013;<lpage>320</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1016/s2213-2600(14)70033-5</pub-id>
<pub-id pub-id-type="pmid">24717627</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Knaul</surname><given-names>J. K.</given-names></name><name><surname>Jorg</surname><given-names>S.</given-names></name><name><surname>Oberbeck-Mueller</surname><given-names>D.</given-names></name><name><surname>Heinemann</surname><given-names>E.</given-names></name><name><surname>Scheuermann</surname><given-names>L.</given-names></name><name><surname>Brinkmann</surname><given-names>V.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Lung-Residing Myeloid-Derived Suppressors Display Dual Functionality in Murine Pulmonary Tuberculosis</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>190</volume> (<issue>9</issue>), <fpage>1053</fpage>&#x02013;<lpage>1066</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1164/rccm.201405-0828OC</pub-id>
<pub-id pub-id-type="pmid">25275852</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Locovei</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Dahl</surname><given-names>G.</given-names></name></person-group> (<year>2006</year>). <article-title>Activation of Pannexin 1 Channels by ATP Through P2Y Receptors and by Cytoplasmic Calcium</article-title>. <source>FEBS Lett.</source>
<volume>580</volume> (<issue>1</issue>), <fpage>239</fpage>&#x02013;<lpage>244</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1016/j.febslet.2005.12.004</pub-id>
<pub-id pub-id-type="pmid">16364313</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lovewell</surname><given-names>R. R.</given-names></name><name><surname>Baer</surname><given-names>C. E.</given-names></name><name><surname>Mishra</surname><given-names>B. B.</given-names></name><name><surname>Smith</surname><given-names>C. M.</given-names></name><name><surname>Sassetti</surname><given-names>C. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Granulocytes Act as a Niche for Mycobacterium Tuberculosis Growth</article-title>. <source>Mucosal Immunol</source>. <volume>4</volume>, <fpage>229</fpage>&#x02013;<lpage>241</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1038/s41385-020-0300-z</pub-id>
</mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mariathasan</surname><given-names>S.</given-names></name><name><surname>Weiss</surname><given-names>D. S.</given-names></name><name><surname>Newton</surname><given-names>K.</given-names></name><name><surname>McBride</surname><given-names>J.</given-names></name><name><surname>O&#x02019;Rourke</surname><given-names>K.</given-names></name><name><surname>Roose-Girma</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>Cryopyrin Activates the Inflammasome in Response to Toxins and ATP</article-title>. <source>Nature</source>
<volume>440</volume> (<issue>7081</issue>), <fpage>228</fpage>&#x02013;<lpage>232</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1038/nature04515</pub-id>
<pub-id pub-id-type="pmid">16407890</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McWilliam</surname><given-names>A. S.</given-names></name><name><surname>Nelson</surname><given-names>D.</given-names></name><name><surname>Thomas</surname><given-names>J. A.</given-names></name><name><surname>Holt</surname><given-names>P. G.</given-names></name></person-group> (<year>1994</year>). <article-title>Rapid Dendritic Cell Recruitment is a Hallmark of the Acute Inflammatory Response At Mucosal Surfaces</article-title>. <source>J. Exp. Med.</source>
<volume>179</volume> (<issue>4</issue>), <fpage>1331</fpage>&#x02013;<lpage>1336</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1084/jem.179.4.1331</pub-id>
<pub-id pub-id-type="pmid">8145044</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Misharin</surname><given-names>A. V.</given-names></name><name><surname>Morales-Nebreda</surname><given-names>L.</given-names></name><name><surname>Mutlu</surname><given-names>G. M.</given-names></name><name><surname>Budinger</surname><given-names>G. R.</given-names></name><name><surname>Perlman</surname><given-names>H.</given-names></name></person-group> (<year>2013</year>). <article-title>Flow Cytometric Analysis of Macrophages and Dendritic Cell Subsets in the Mouse Lung</article-title>. <source>Am. J. Respir. Cell Mol. Biol.</source>
<volume>49</volume> (<issue>4</issue>), <fpage>503</fpage>&#x02013;<lpage>510</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1165/rcmb.2013-0086MA</pub-id>
<pub-id pub-id-type="pmid">23672262</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peng</surname><given-names>W.</given-names></name><name><surname>Cotrina</surname><given-names>M. L.</given-names></name><name><surname>Han</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Bekar</surname><given-names>L.</given-names></name><name><surname>Blum</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Systemic Administration of an Antagonist of the ATP-sensitive Receptor P2X7 Improves Recovery After Spinal Cord Injury</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<volume>106</volume> (<issue>30</issue>), <fpage>12489</fpage>&#x02013;<lpage>12493</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0902531106</pub-id>
<pub-id pub-id-type="pmid">19666625</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prasad</surname><given-names>K.</given-names></name><name><surname>Singh</surname><given-names>M. B.</given-names></name><name><surname>Ryan</surname><given-names>H.</given-names></name></person-group> (<year>2016</year>). <article-title>Corticosteroids for Managing Tuberculous Meningitis</article-title>. <source>Cochrane Database Syst. Rev.</source>
<volume>4</volume> (<issue>4</issue>), <fpage>Cd002244</fpage>. &#x000a0;<pub-id pub-id-type="doi">10.1002/14651858.CD002244.pub4</pub-id>
<pub-id pub-id-type="pmid">27121755</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Proietti</surname><given-names>M.</given-names></name><name><surname>Cornacchione</surname><given-names>V.</given-names></name><name><surname>Rezzonico Jost</surname><given-names>T.</given-names></name><name><surname>Romagnani</surname><given-names>A.</given-names></name><name><surname>Faliti</surname><given-names>C. E.</given-names></name><name><surname>Perruzza</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>ATP-Gated Ionotropic P2X7 Receptor Controls Follicular T Helper Cell Numbers in Peyer&#x02019;s Patches to Promote Host-Microbiota Mutualism</article-title>. <source>Immunity</source>
<volume>41</volume> (<issue>5</issue>), <fpage>789</fpage>&#x02013;<lpage>801</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1016/j.immuni.2014.10.010</pub-id>
<pub-id pub-id-type="pmid">25464855</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>M. E.</given-names></name><name><surname>Phipson</surname><given-names>B.</given-names></name><name><surname>Wu</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Law</surname><given-names>C. W.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Limma Powers Differential Expression Analyses for RNA-sequencing and Microarray Studies</article-title>. <source>Nucleic Acids Res.</source>
<volume>43</volume> (<issue>7</issue>), <fpage>e47</fpage>. &#x000a0;<pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id>
<pub-id pub-id-type="pmid">25605792</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sakai</surname><given-names>S.</given-names></name><name><surname>Kauffman</surname><given-names>K. D.</given-names></name><name><surname>Schenkel</surname><given-names>J. M.</given-names></name><name><surname>McBerry</surname><given-names>C. C.</given-names></name><name><surname>Mayer-Barber</surname><given-names>K. D.</given-names></name><name><surname>Masopust</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Cutting Edge: Control of Mycobacterium Tuberculosis Infection by a Subset of Lung Parenchyma-Homing CD4 T Cells</article-title>. <source>J. Immunol.</source>
<volume>192</volume> (<issue>7</issue>), <fpage>2965</fpage>&#x02013;<lpage>2969</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.4049/jimmunol.1400019</pub-id>
<pub-id pub-id-type="pmid">24591367</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Salles</surname><given-names>E. M.</given-names></name><name><surname>Menezes</surname><given-names>M. N.</given-names></name><name><surname>Siqueira</surname><given-names>R.</given-names></name><name><surname>Borges da Silva</surname><given-names>H.</given-names></name><name><surname>Amaral</surname><given-names>E. P.</given-names></name><name><surname>Castillo-Mendez</surname><given-names>S. I.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>P2X7 Receptor Drives Th1 Cell Differentiation and Controls the Follicular Helper T Cell Population to Protect Against Plasmodium Chabaudi Malaria</article-title>. <source>PloS Pathog.</source>
<volume>13</volume> (<issue>8</issue>), <fpage>e1006595</fpage>. &#x000a0;<pub-id pub-id-type="doi">10.1371/journal.ppat.1006595</pub-id>
<pub-id pub-id-type="pmid">28859168</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sborgi</surname><given-names>L.</given-names></name><name><surname>R&#x000fc;hl</surname><given-names>S.</given-names></name><name><surname>Mulvihill</surname><given-names>E.</given-names></name><name><surname>Pipercevic</surname><given-names>J.</given-names></name><name><surname>Heilig</surname><given-names>R.</given-names></name><name><surname>Stahlberg</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>GSDMD Membrane Pore Formation Constitutes the Mechanism of Pyroptotic Cell Death</article-title>. <source>EMBO J.</source>
<volume>35</volume> (<issue>16</issue>), <fpage>1766</fpage>&#x02013;<lpage>1778</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.15252/embj.201694696</pub-id>
<pub-id pub-id-type="pmid">27418190</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schutz</surname><given-names>C.</given-names></name><name><surname>Davis</surname><given-names>A. G.</given-names></name><name><surname>Sossen</surname><given-names>B.</given-names></name><name><surname>Lai</surname><given-names>R. P.</given-names></name><name><surname>Ntsekhe</surname><given-names>M.</given-names></name><name><surname>Harley</surname><given-names>Y. X.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Corticosteroids as an Adjunct to Tuberculosis Therapy</article-title>. <source>Expert Rev. Respir. Med.</source>
<volume>12</volume> (<issue>10</issue>), <fpage>881</fpage>&#x02013;<lpage>891</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1080/17476348.2018.1515628</pub-id>
<pub-id pub-id-type="pmid">30138039</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shah</surname><given-names>N. S.</given-names></name><name><surname>Wright</surname><given-names>A.</given-names></name><name><surname>Bai</surname><given-names>G. H.</given-names></name><name><surname>Barrera</surname><given-names>L.</given-names></name><name><surname>Boulahbal</surname><given-names>F.</given-names></name><name><surname>Mart&#x000ed;n-Casabona</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Worldwide Emergence of Extensively Drug-Resistant Tuberculosis</article-title>. <source>Emerg. Infect. Dis.</source>
<volume>13</volume> (<issue>3</issue>), <fpage>380</fpage>&#x02013;<lpage>387</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.3201/eid1303.061400</pub-id>
<pub-id pub-id-type="pmid">17552090</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shieh</surname><given-names>C. H.</given-names></name><name><surname>Heinrich</surname><given-names>A.</given-names></name><name><surname>Serchov</surname><given-names>T.</given-names></name><name><surname>van Calker</surname><given-names>D.</given-names></name><name><surname>Biber</surname><given-names>K.</given-names></name></person-group> (<year>2014</year>). <article-title>P2X7-Dependent, But Differentially Regulated Release of IL-6, CCL2, and TNF-&#x003b1; in Cultured Mouse Microglia</article-title>. <source>Glia</source>
<volume>62</volume> (<issue>4</issue>), <fpage>592</fpage>&#x02013;<lpage>607</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1002/glia.22628</pub-id>
<pub-id pub-id-type="pmid">24470356</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Shi</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Cleavage of GSDMD by Inflammatory Caspases Determines Pyroptotic Cell Death</article-title>. <source>Nature</source>
<volume>526</volume> (<issue>7575</issue>), <fpage>660</fpage>&#x02013;<lpage>665</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1038/nature15514</pub-id>
<pub-id pub-id-type="pmid">26375003</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tobin</surname><given-names>D. M.</given-names></name></person-group> (<year>2015</year>). <article-title>Host-Directed Therapies for Tuberculosis</article-title>. <source>Cold Spring Harb. Perspect. Med.</source>
<volume>5</volume> (<issue>10</issue>). &#x000a0;<pub-id pub-id-type="doi">10.1101/cshperspect.a021196</pub-id>
</mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tsenova</surname><given-names>L.</given-names></name><name><surname>Singhal</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Effects of Host-Directed Therapies on the Pathology of Tuberculosis</article-title>. <source>J. Pathol.</source>
<volume>250</volume> (<issue>5</issue>), <fpage>636</fpage>&#x02013;<lpage>646</lpage>. &#x000a0;<pub-id pub-id-type="doi">10.1002/path.5407</pub-id>
<pub-id pub-id-type="pmid">32108337</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tsiganov</surname><given-names>E. N.</given-names></name><name><surname>Verbina</surname><given-names>E. M.</given-names></name><name><surname>Radaeva</surname><given-names>T. V.</given-names></name><name><surname>Sosunov</surname><given-names>V. V.</given-names></name><name><surname>Kosmiadi</surname><given-names>G. A.</given-names></name><name><surname>Nikitina</surname><given-names>I. Y.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Gr-1dimCD11b+ Immature Myeloid-Derived Suppressor Cells But Not Neutrophils Are Markers of Lethal Tuberculosis Infection in Mice</article-title>. <source>J. Immunol.</source>
<volume>7</volume>, <fpage>7</fpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1301365</pub-id>
</mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Whitfield</surname><given-names>M. G.</given-names></name><name><surname>Soeters</surname><given-names>H. M.</given-names></name><name><surname>Warren</surname><given-names>R. M.</given-names></name><name><surname>York</surname><given-names>T.</given-names></name><name><surname>Sampson</surname><given-names>S. L.</given-names></name><name><surname>Streicher</surname><given-names>E. M.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis</article-title>. <source>PloS One</source>
<volume>10</volume> (<issue>7</issue>), <fpage>e0133869</fpage>. &#x000a0;<pub-id pub-id-type="doi">10.1371/journal.pone.0133869</pub-id>
<pub-id pub-id-type="pmid">26218737</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="book">
<person-group person-group-type="author"><collab>World Health Organization</collab></person-group> (<year>2020</year>). <source>Global Tuberculosis Report 2020</source>. <publisher-loc>Geneva</publisher-loc>.</mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A.</given-names></name><name><surname>Rao</surname><given-names>M.</given-names></name><name><surname>Dodoo</surname><given-names>E.</given-names></name><name><surname>Maeurer</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Potential of Immunomodulatory Agents as Adjunct Host-Directed Therapies for Multidrug-Resistant Tuberculosis</article-title>. <source>BMC Med.</source>
<volume>14</volume>, <fpage>89</fpage>. &#x000a0;<pub-id pub-id-type="doi">10.1186/s12916-016-0635-1</pub-id>
<pub-id pub-id-type="pmid">27301245</pub-id></mixed-citation></ref></ref-list></back></article>